Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1927 1
1928 1
1929 2
1930 1
1931 2
1933 1
1935 1
1936 2
1940 1
1941 2
1944 1
1945 3
1946 5
1947 3
1948 1
1949 1
1950 5
1951 5
1952 2
1953 6
1954 10
1955 3
1956 6
1957 11
1958 7
1959 4
1960 7
1961 6
1962 11
1963 5
1964 12
1965 22
1966 14
1967 10
1968 13
1969 12
1970 11
1971 19
1972 15
1973 14
1974 19
1975 29
1976 25
1977 15
1978 24
1979 23
1980 23
1981 23
1982 27
1983 26
1984 30
1985 48
1986 48
1987 106
1988 152
1989 224
1990 257
1991 311
1992 330
1993 371
1994 455
1995 496
1996 533
1997 521
1998 549
1999 572
2000 652
2001 766
2002 729
2003 797
2004 826
2005 886
2006 881
2007 960
2008 961
2009 969
2010 1040
2011 1155
2012 1173
2013 1247
2014 1261
2015 1161
2016 1231
2017 1179
2018 1219
2019 1232
2020 1436
2021 329
Text availability
Article attribute
Article type
Publication date

Search Results

25,185 results
Results by year
Filters applied: . Clear all The following term was not found in PubMed: Fang-Tzu
Page 1
Did you mean fan, tzu pei (3 results)?
Plasminogen activator inhibitor-1 in cancer research.
Li S, Wei X, He J, Tian X, Yuan S, Sun L. Li S, et al. Biomed Pharmacother. 2018 Sep;105:83-94. doi: 10.1016/j.biopha.2018.05.119. Epub 2018 May 28. Biomed Pharmacother. 2018. PMID: 29852393 Review.
Furthermore, there are many tumor promoting factors involved in the modulation of PAI-1 expression and activity, which will strengthen the pro-tumorigenic roles of PAI-1. Undoubtedly, PAI-1 may be a promising target for therapeutic intervention of specific ca …
Furthermore, there are many tumor promoting factors involved in the modulation of PAI-1 expression and activity, which will strengthe …
Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphisms and risk of venous thromboembolism - a meta-analysis and systematic review.
Zhang Q, Jin Y, Li X, Peng X, Peng N, Song J, Xu M. Zhang Q, et al. Vasa. 2020 Mar;49(2):141-146. doi: 10.1024/0301-1526/a000839. Epub 2020 Jan 10. Vasa. 2020. PMID: 31920171 Free article.
Results: A total of 27 studies, with 3135 patients and 5346 controls were included. Overall, the variant PAI-1 4G/4G and PAI-1 4G/5G was associated with venous thromboembolism risk, compared with the PAI-1 5G/5G allele in the populations included in the analy …
Results: A total of 27 studies, with 3135 patients and 5346 controls were included. Overall, the variant PAI-1 4G/4G and PAI-1 …
Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition.
Sillen M, Declerck PJ. Sillen M, et al. Front Cardiovasc Med. 2020 Dec 22;7:622473. doi: 10.3389/fcvm.2020.622473. eCollection 2020. Front Cardiovasc Med. 2020. PMID: 33415130 Free PMC article. Review.
In the prospect of treating the broad range of PAI-1-related pathologies, many efforts have been devoted to developing PAI-1 inhibitors. ...This review will provide an overview of the structural insights into PAI-1 functionality and modulation thereof and wil …
In the prospect of treating the broad range of PAI-1-related pathologies, many efforts have been devoted to developing PAI-1 i …
Nanomaterials for photoacoustic imaging in the second near-infrared window.
Huang K , Zhang Y , Lin J , Huang P . Huang K , et al. Biomater Sci. 2019 Jan 29;7(2):472-479. doi: 10.1039/c8bm00642c. Biomater Sci. 2019. PMID: 30255873 Review.
This review focuses on the latest achievements on PAI in the NIR-II region. The advantages of shifting PAI from NIR-I to NIR-II is first compared, followed by discussions on nanomaterials as contrast agents for NIR-II PAI. In the end, the challenges and persp …
This review focuses on the latest achievements on PAI in the NIR-II region. The advantages of shifting PAI from NIR-I to NIR-I …
Rare monogenic causes of primary adrenal insufficiency.
Narumi S. Narumi S. Curr Opin Endocrinol Diabetes Obes. 2018 Jun;25(3):172-177. doi: 10.1097/MED.0000000000000401. Curr Opin Endocrinol Diabetes Obes. 2018. PMID: 29373482 Review.
PURPOSE OF REVIEW: Monogenic disorders play significant roles in the pathogenesis of childhood-onset primary adrenal insufficiency (PAI). The most common form of PAI is congenital adrenal hyperplasia (CAH), which includes the enzymatic defects of the steroidogenic p …
PURPOSE OF REVIEW: Monogenic disorders play significant roles in the pathogenesis of childhood-onset primary adrenal insufficiency (PAI
High-speed dual-view photoacoustic imaging pen.
Zhang W, Ma H, Cheng Z, Wang Z, Xiong K, Yang S. Zhang W, et al. Opt Lett. 2020 Apr 1;45(7):1599-1602. doi: 10.1364/OL.388863. Opt Lett. 2020. PMID: 32235952
Today, photoacoustic imaging (PAI) is widely used to study diseases in the skin, brain, cardiovascular, and other parts. ...The PAI pen can be handheld and can perform forward detection and lateral detection. ...
Today, photoacoustic imaging (PAI) is widely used to study diseases in the skin, brain, cardiovascular, and other parts. ...The PA
Adipose Tissue-Derived Plasminogen Activator Inhibitor-1 Function and Regulation.
Kaji H. Kaji H. Compr Physiol. 2016 Sep 15;6(4):1873-1896. doi: 10.1002/cphy.c160004. Compr Physiol. 2016. PMID: 27783862 Review.
PAI-1 induces fibrinogenesis by suppressing intravascular and tissue fibrinolysis. Moreover, PAI-1 exerts various cellular effects independently of fibrinolysis. ...
PAI-1 induces fibrinogenesis by suppressing intravascular and tissue fibrinolysis. Moreover, PAI-1 exerts various cellular eff
Deficiency of Plasminogen Activator Inhibitor Type 2 Limits Brain Edema Formation after Traumatic Brain Injury.
Griemert EV, Hedrich J, Hirnet T, Thal SC. Griemert EV, et al. J Neurotrauma. 2019 Jul 15;36(14):2272-2278. doi: 10.1089/neu.2018.6126. Epub 2019 Mar 28. J Neurotrauma. 2019. PMID: 30755137
Plasminogen activator inhibitor-2 (PAI-2/SerpinB2) inhibits extracellular urokinase plasminogen activator (uPA). ...To investigate a potentially detrimental influence of PAI-2 on secondary post-traumatic processes, male PAI-2-deficient (PAI-2-KO) and w …
Plasminogen activator inhibitor-2 (PAI-2/SerpinB2) inhibits extracellular urokinase plasminogen activator (uPA). ...To investigate a …
Tuberculosis: the story after the Primer.
Pai M. Pai M. Nat Rev Dis Primers. 2020 Apr 23;6(1):29. doi: 10.1038/s41572-020-0161-5. Nat Rev Dis Primers. 2020. PMID: 32327661 No abstract available.
The association between plasminogen activator inhibitor type-1 and clinical outcome in paediatric sepsis.
Pudjiadi AH, Adhyanisitha K, Pusponegoro HD, Suyoko DEM, Satari HI, Kaswandani N. Pudjiadi AH, et al. Blood Coagul Fibrinolysis. 2020 Sep;31(6):377-381. doi: 10.1097/MBC.0000000000000931. Blood Coagul Fibrinolysis. 2020. PMID: 32815912
Among survivors, mean PAI-1 level on day-1 was statistically higher than PAI-1 level on day-4 (82.47 44.43 vs. 58.39 32.98 ng/ml), P = 0.021. ...Changes in PAI-1 levels in nonsurvivors did not differ. PAI-1 level was positively correlated with DIC scor …
Among survivors, mean PAI-1 level on day-1 was statistically higher than PAI-1 level on day-4 (82.47 44.43 vs. 58.39 32.98 ng/ …
25,185 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page